Quarterly ResultMay 11, 2026, 04:48 PM
Coherus Oncology Q1 Net Revenue $12.31M; Net Loss $(38.33)M
AI Summary
Coherus Oncology reported a net revenue of $12.31 million for the first quarter of 2026, a significant increase from $7.60 million in the prior year. The company's net loss improved to $(38.33) million, or $(0.28) per share, compared to a net loss of $(56.57) million, or $(0.49) per share, in Q1 2025. This improvement was supported by increased sales of LOQTORZI and a public offering that generated $53.65 million in net proceeds, boosting cash reserves despite higher operating cash burn.
Key Highlights
- Net revenue increased to $12.31 million in Q1 2026 from $7.60 million in Q1 2025.
- Net loss improved to $(38.33) million in Q1 2026 from $(56.57) million in Q1 2025.
- Net loss per share was $(0.28) for Q1 2026, an improvement from $(0.49) in Q1 2025.
- LOQTORZI net product revenue was $11.80 million in Q1 2026, up from $7.35 million in Q1 2025.
- Cash and cash equivalents rose to $115.24 million as of March 31, 2026.
- Proceeds from a public offering of common stock totaled $53.65 million.
- Net cash used in operating activities increased to $(57.89) million in Q1 2026.